Masaya Tachibana
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Response to Comment on "Population Pharmacokinetics of Valemetostat and Exposure-Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma".
Journal: Journal of clinical pharmacology
Published: October 28, 2025
Concentration-QTc Analysis of Valemetostat in Patients With Hematologic Malignancies.
Journal: Clinical and translational science
Published: July 10, 2025
Population Pharmacokinetics of Valemetostat and Exposure-Response Analyses of Efficacy and Safety in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma.
Journal: Journal of clinical pharmacology
Published: June 16, 2025
Physiologically Based Pharmacokinetic Modeling of Valemetostat to Inform Dose Recommendations When Coadministered With CYP3A/P-gp Modulators.
Journal: Clinical and translational science
Published: March 20, 2025
Effect of Rifampicin on the Pharmacokinetics of Valemetostat and Its Primary Metabolite: A Phase 1 Study in Healthy Participants.
Journal: Clinical and translational science
Published: March 20, 2025
Effect of Valemetostat on the Pharmacokinetics of Midazolam and Digoxin: A Phase 1 Drug-Drug Interaction Study in Patients With Non-Hodgkin Lymphoma.
Journal: Clinical and translational science
Published: March 11, 2025
Effect of Mild to Moderate Hepatic Impairment on Valemetostat Pharmacokinetics: An Open-Label, Phase I Study.
Journal: Clinical pharmacology in drug development
Published: January 17, 2025
Pharmacokinetics, metabolism, and excretion of [14C]-valemetostat in healthy male participants, and in vitro plasma protein binding.
Journal: Cancer chemotherapy and pharmacology
Published: November 01, 2024
Population pharmacokinetics of total and unbound valemetostat and platelet dynamics in healthy volunteers and patients with non-Hodgkin lymphoma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: March 04, 2024
Bayesian sparse regression for exposure-response analyses of efficacy and safety endpoints to justify the clinical dose of valemetostat for adult T-cell leukemia/lymphoma.
Journal: CPT: pharmacometrics & systems pharmacology
Published: March 04, 2024
Valemetostat monotherapy in patients with relapsed or refractory non-Hodgkin lymphoma: a first-in-human, multicentre, open-label, single-arm, phase 1 study.
Journal: The Lancet. Oncology
Published: February 29, 2024
Safety, Tolerability, and Pharmacokinetics of Valemetostat Tablets and the Effect of Food on Valemetostat Pharmacokinetics in Healthy Subjects: Two Phase 1 Studies.
Journal: Clinical pharmacology in drug development
Published: May 19, 2023
Last Updated: 09/26/2026